Pancreatitis (acute)

Acute pancreatitis is sudden inflammation of the pancreas. It presents as severe, persistent pain in the upper abdomen that often bores through to the back, usually with nausea and vomiting, and it typically worsens rather than easing. It is a medical emergency, and it is the adverse event most likely to end GLP-1 treatment permanently.

Every GLP-1 label in this category carries the same Warnings and Precautions entry: acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists, and the drug should be discontinued if pancreatitis is suspected. The postmarketing sections go further, listing hemorrhagic and necrotizing pancreatitis, sometimes resulting in death. That is stark language, and it reflects rare but real outcomes.

Two things shape the individual risk picture. Gallstones are a leading cause of pancreatitis in the general population, and GLP-1 medications independently raise gallstone risk — so the two warnings on the label are connected. Heavy alcohol use and very high triglycerides are the other major contributors, and both are worth discussing before starting.

The confusion worth clearing is between pancreatitis and ordinary GLP-1 stomach upset, which is common and usually mild. The distinguishing features are severity, persistence and location: pain that is severe, does not let up, sits high in the abdomen and radiates to the back is not nausea. Do not wait to see if it passes. Separately, a raised lipase or amylase on a routine blood test without symptoms is a common finding on these drugs and is not the same thing as pancreatitis.

Tell your prescriber about any prior episode of pancreatitis, any gallbladder history, your alcohol intake and your triglyceride level before the first dose. Ask what symptoms mean going to an emergency room rather than messaging the clinic. Our pancreatitis safety review and lipase and amylase guide cover both questions.